Skip to main content

Advertisement

Table 2 Anthropometric, clinical, and biochemical characteristics of patient sample: distribution by gender in diabetic (n = 247) and non-diabetic (n = 2212) individuals

From: Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study

  Women (1308/128) Men (904/119) Total
Age (years)    
• Non-diabetic 47.6 ± 15.9 48.2 ± 16.0 47.9 ± 15.9
• Diabetic 64.4 ± 10.7 62.4 ± 10.8 63.4 ± 10.7
Waist circumference (cm)    
• Non-diabetic*** 86.8 ± 13.2 96.3 ± 11.3 90.6 ± 13.3
• Diabetic* 101.5 ± 13.5 105.0 ± 11.4 103.1 ± 12.5
BMI (kg/m2)    
• Non-diabetic*** 26.9 ± 5.4 27.8 ± 4.5 27.3 ± 5.1
• Diabetic*** 32.2 ± 5.6 29.4 ± 4.4 31.1 ± 5.2
Systolic blood pressure (mmHg)    
• Non-diabetic*** 125.4 ± 21.0 135.8 ± 19.0 129.6 ± 20.8
• Diabetic 145.9 ± 21.1 148.6 ± 21.2 147.3 ± 21.1
Diastolic blood pressure (mmHg)    
• Non-diabetic*** 76.6 ± 11.0 81.1 ± 11.4 78.4 ± 11.4
• Diabetic 82.1 ± 11.7 82.1 ± 10.7 82.1 ± 11.2
Triglycerides (mmol l-1)    
• Non-diabetic*** 1.0 ± 0.6 1.3 ± 0.9 1.1 ± 0.7
• Diabetic 1.5 ± 0.8 1.9 ± 1.9 1.7 ± 1.4
HDL-Cholesterol (mmol/L)    
• Non-diabetic*** 2.0 ± 0.5 1.7 ± 0.4 1.9 ± 0.5
• Diabetic** 1.7 ± 0.4 1.6 ± 0.4 1.8 ± 0.4
Fasting insulin (U/l)    
• Non-diabetic** 7.7 ± 4.6 8.5 ± 5.2 8.0 ± 4.9
• Diabetic 11.9 ± 6.2 10.9 ± 6.5 11.4 ± 6.3
Fasting plasma glucose (mmol l-1)    
• Non-diabetic*** 4.9 ± 0.6 5.1 ± 0.6 5.0 ± 0.6
• Diabetic* 7.8 ± 2.4 8.1 ± 2.5 8.0 ± 2.5
HOMA-IR (units)    
• Non-diabetic 1.9 ± 1.0 2.1 ± 1.2 2.0 ± 1.1
• Diabetic* 1.9 ± 1.0 1.7 ± 1.1 1.9 ± 1.1
Metabolic syndrome    
ATPIII** 11.1% (159) 14.9% (152) 12.7% (311)
• Non-diabetic** 7.6% (99) 11.1% (100) 9.0% (199)
• Diabetic 46.9% (60) 43.7% (52) 45.3% (112)
IDF*** 12.1% (174) 19.2% (196) 15.0% (370)
• Non-diabetic*** 8.7% (114) 14.9% (135) 11.3% (249)
• Diabetic 46.9% (60) 51.3% (61) 49.0% (121)
  1. Data are presented as mean ± standard deviation, or percentages (n). BMI, body mass index; HDL-Cholesterol, high density lipoprotein-Cholesterol; HOMA-IR, homeostasis model assessment of IR; ATPIII, Third Adult Treatment Panel; IDF, International Diabetes Federation.
  2. Contrast of characteristics by gender was done with the follow statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001.